A FRET profile of modifications in Estrogen Receptor α associated with resistance to anti-estrogens Submitted 10

[1]  K. Jirström,et al.  Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. , 2006, Journal of the National Cancer Institute.

[2]  R. Tsien,et al.  The Fluorescent Toolbox for Assessing Protein Location and Function , 2006, Science.

[3]  A. Pike.  Lessons learnt from structural studies of the oestrogen receptor. , 2006, Best practice & research. Clinical endocrinology & metabolism.

[4]  C. J. Barnes,et al.  P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. , 2006, Cancer research.

[5]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[6]  T. Willson,et al.  Structural basis for an unexpected mode of SERM-mediated ER antagonism. , 2005, Molecular cell.

[7]  J. Robertson,et al.  Endocrine treatment options for advanced breast cancer--the role of fulvestrant. , 2005, European journal of cancer.

[8]  M. Castiglione‐Gertsch,et al.  The choice of systemic adjuvant therapy in receptor-positive early breast cancer. , 2005, European journal of cancer.

[9]  D. McDonnell,et al.  The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  J. Robertson.  Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. , 2004, Cancer treatment reviews.

[11]  Vincent Laudet,et al.  Principles for modulation of the nuclear receptor superfamily , 2004, Nature Reviews Drug Discovery.

[12]  A. Floore,et al.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. , 2004, Cancer cell.

[13]  D. Vanderwall,et al.  Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds. , 2004, Molecular endocrinology.

[14]  C. Osborne,et al.  Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action , 2004, British Journal of Cancer.

[15]  J. Robertson,et al.  Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. , 2003, European journal of cancer.

[16]  R. Agami,et al.  The tumor-suppressive functions of the human INK4A locus. , 2003, Cancer cell.

[17]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[18]  F. Lallemand,et al.  Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells , 2002, Oncogene.

[19]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[20]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C K Osborne,et al.  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  V. Jordan,et al.  Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor α , 2002, British Journal of Cancer.

[23]  Hong Liu,et al.  Re: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol and the two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. , 2002, Journal of the National Cancer Institute.

[24]  Patricia A. Dyck,et al.  Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. , 2002, Cancer research.

[25]  W. Miller.  Regulatory Subunits of PKA and Breast Cancer , 2002, Annals of the New York Academy of Sciences.

[26]  D. Bentrem,et al.  Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[28]  J. Pezzuto,et al.  Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. , 2001, Cancer research.

[29]  D. McDonnell,et al.  The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators* , 2001, The Journal of Biological Chemistry.

[30]  R. Habets,et al.  Monitoring Agonist-induced Phospholipase C Activation in Live Cells by Fluorescence Resonance Energy Transfer* , 2001, The Journal of Biological Chemistry.

[31]  C K Osborne,et al.  Selective estrogen receptor modulators: structure, function, and clinical use. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Fowlkes,et al.  Peptide antagonists of the human estrogen receptor. , 1999, Science.

[33]  H. Pols,et al.  Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. , 1999, Biochemical and biophysical research communications.

[34]  H Grøn,et al.  Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[36]  J. Trowsdale,et al.  HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading , 1997, Current Biology.

[37]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[38]  D. Picard,et al.  Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. , 1996, The EMBO journal.

[39]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[40]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Hordijk,et al.  cAMP abrogates the p21ras-mitogen-activated protein kinase pathway in fibroblasts. , 1994, The Journal of biological chemistry.

[42]  S. Khosla,et al.  Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. , 2005, Molecular endocrinology.

[43]  J. Hartman,et al.  Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  B. Katzenellenbogen,et al.  Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. , 2004, Molecular cell.

[45]  R. Schiff,et al.  Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  K. Pritchard.  Endocrine therapy of advanced disease: analysis and implications of the existing data. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  R. Coombes,et al.  Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. , 1999, Molecular and cellular biology.

[48]  J. Gustafsson,et al.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. , 1997, Science.